Search

Background The aim of this prospective study was to determine if commonly used risk stratification models can predict total hospital costs in cardiac surgical patients. Methods Between October 1st and December 31st 2003, all consecutive adult patients undergoing cardiac surgery on CPB at our institution were classified using seven risk stratification scoring systems: EuroSCORE, Cleveland, Parsonnet, Ontario, French, Pons, and CABDEAL. Total hospital costs for each patient were calculated on a daily basis including preoperative diagnostic tests, operating room costs, disposable materials, drugs, blood components, costs for personnel, and hospital fixed-costs. Linear regression analysis was used to determine the correlation between costs and the seven risk stratifications models as well as length of stay (LOS) on ICU. The Spearman correlation coefficient was calculated from the regression line, and an analysis of residuals was performed to determine the quality of the regression. Results A total of 252 patients were operated for CABG (n=175), valve (n=39), CABG plus valve (n=21), thoracic aorta (n = 13) and miscellaneous (2 myxoma, 1 ASD, 1 pulmonary embolism). Mean age of the patients was 66.0 ′ 11.4 years, 29.4% were female. LOS on ICU was 3.3 ′ 6.3 days and the 30-day mortality rate was 6.7%. Spearman correlation between the seven risk stratification models and hospital costs was below r = 0.32 (p = 0.0001), but was r=0.94 (p = 0.0001) between ICU LOS and costs. Conclusions Total hospital costs can be identified by length of ICU stay. None of the common risk stratification models accurately predicted total hospital costs in cardiac surgical patients.

In Vorstudien konnten wir belegen, dass kontinuierliche antegrade Koronarperfusion mit warmen ultrakurz wirkendem Beta-Blocker (Esmolol/ES) angereichertem Blut den funktionellen und strukturellen Schutz der Herzmuskelzellen unter aortokoronaren Bypassoperation im Vergleich mit konventioneller Brettschneider-Kardioplegie (BKP) verbessert. Ziel unserer Studie war der Vergleich der beiden Protektionstechniken in Bezug auf die postoperativen klinischen Ergebnisse. Hierfur analysierten wir 150 aufeinanderfolgende Patienten retrospektiv, die mit herkommlicher Brettschneidertechnik protektioniert worden waren und verglichen diese mit 150 Patienten, die mit kontinuierlichen warmen Blut, welches mit einem ultrakurz wirkenden Beta-Blocker angereichert war, am schlagenden Herzen mit arteriellen und venosen koronaren Bypassen versorgt worden waren. Beide Gruppen zeigten vergleichbare Werte fur Alter, Geschlecht, praoperativer linksventrikularer Funktion, praoperatives Vorhandensein von Niereninsuffizienz und neurologischen Vorschadigungen. Sie wurden im gleichen Zeitraum operiert. Es ergaben sich keine signifikanten Unterschiede zwischen den Gruppen in Bezug auf die perioperative Infarktrate, Gabe von positiv inotroper Medikation, Anwendung von kreislaufunterstutzenden Systemen, Dauer der Nachbeatmung, Dauer des postoperativen Intensivstationsaufenthaltes, des Mobilisationszeitraum, Haufigkeit der postoperativer Niereninsuffizienz, Herzrhythmusstorungen, neurologischen Auffalligkeiten, Infektionshaufigkeit und 30-Tage-Mortalitat. Esmolol-Patienten (ES) wurden signifikant seltener auf die Intensivstation zuruckverlegt (3 von 150=2,2% [95% Konfidenzinterval: 0-4-2%] gegen 13 von 150=8,7% [KI 4,2–13,2%]; p=0,010). Auserdem wiesen ES-Patienten eine kurzere Krankenhausverweildauer auf (ES: 12,3±4,8Tage [95%-Konfidenzinterval 11,5–13,0] im Vergleich BKP-Patienten 13,5±3,8 [95%-KI 12,9–14,1] Tage; p=0,013). Damit wurden 159 Patiententage auf Normalstation gespart. Zusatzlich lagen die Kosten fur die Beta-Blockade-Behandlung bei durchschnittlich 60 Euro im Vergleich zu 120 Euro fur die Brettschneider-Kardioplegie-Technik pro Patient. Unsere Daten zeigten keine Unterschiede im klinischen Ergebnis zwischen den Gruppen, jedoch sehr wohl einen Unterschied in den tatsachlichen Kosten.

BACKGROUND The optimal hematocrit (HCT) value after coronary artery bypass grafting on cardiopulmonary bypass (CPB) has not yet been established. The purpose of our retrospective study was to investigate the association between HCr at the time of entry into the ICU and perioperative Ml rate. METHODS We reviewed the charts of 500 consecutive coronary artery surgery patients with respect to biometric data, operative procedure, aprotinin or tranexamic acid use, perioperative drainage blood loss and transfusion requirements, perioperative Ml, ICU stay and hospital mortality. Perioperative Ml was defined as new Q-wave on ECG and CK-MB 250U/I. Patients were categorized into three groups depending on their HCr value at the time of entry into the ICU: low (HCTcu 27%): medium (HCr,cu 28% to 32%); high(HCTrcu > or =33%). RESULTS Age, gender distribution, preoperative LV function, and previous Ml rate were similar between the three groups. Low HCT patients (n -133) received 3.1 +/- 1.0 (Mean + SD) grafts during 55 +/- 19 minutes aortic cross clamp time, 98 +/- 31 minutes on CPB (medium HCT: n = 257; 3.2 +/- 1.0 grafts, 51 +/- 20 min cross clamp time, 93 +/- 30 min CPB; p - 0.45 vs. low HCT; high HCT: n = 110: 3.3 +/- 1:0 grafts; 53 +/- 20 min cross clamp time; 104 +/- 38 min CPB; p = 0.02 vs. medium HCT). The perioperative Ml rate was 3.8% in the low, 4.3% in the medium, and 6.4% in the high-HCr group (p =0.59 ). Intraoperative red blood cell and fresh frozen plasma transfusions were similar between the groups. In the low-HCa group, 53.4% of the patients received aprotinin during the procedure (medium HCa: 65.4%; high HCT: 77.3%; p

BACKGROUND Continuous perfusion of the coronary arteries with high-dose beta-blocker (esmolol)-enriched blood has been shown to represent an alternative for myocardial protection during coronary bypass grafting (CABG). Here, we will report on our experience in 200 unselected consecutive cases where this technique was used. METHODS Eighty percent of the patients (age: 63.3 +/- 0.6 years, ejection fraction: 60 +/- 1.2 %, emergency cases: 11 %) had 3-vessel disease, 34 % had a history of myocardial infarction within less than 90 days preoperatively. The Euro score amounted to 6 +/- 0.3. During 52 +/- 1.2 min of aortic cross-clamp time on normothermic cardiopulmonary bypass, 2.9 +/- 0.1 distal anastomoses were performed on a slow hypocontractile beating heart induced by continuous infusion of 788 +/- 20 mg esmolol per operation. All data: mean +/- SEM. RESULTS Postoperatively, patients were ventilated for 25 +/- 5.1 hours and stayed on ICU for 2.3 +/- 0.3 days. The postoperative myocardial infarction rate was 4%. Patients left the hospital after 11.2 +/- 0.4 days. Thirty-day mortality was 2.5 %, and 3-month mortality was 3 %. CONCLUSIONS High-dose beta-blockade is a safe and effective technique in CABG procedures. It may be especially advantageous in high-risk patients.

Various risk scores have been developed for the assessment of operative risk in cardiac surgery. Although risk stratification has been acknowledged as a useful tool to analyze trends in therapy and changes in patient populations, its relevance in assessing the indication for surgery has been questioned. It was the goal of this prospective study to compare 6 common risk scores with regard to the predictive value for mortality in individual patients. Between September 1998 and February 1999 all adult patients undergoing heart surgery were prospectively scored according to the following scores: initial Parsonnet, Cleveland Clinic, French, Euro, Pons, and the Ontario Province Risk score. Early lethality was assessed within 30 days postoperatively. Follow-up was completed in 504 patients. With the exception of the Ontario Province Risk score, lethality in the high risk group was overestimated by all scores, whereas lethality in low to moderate risk groups was underestimated by several scores. Mean scores of surviving and deceased patients showed a broad overlap with high standard deviations. Preoperative risk scores are effective tools for stratification of patient populations and the analysis of surgical outcome. With the aid of risk scores, operative risk can be sufficiently predicted for patient populations or subpopulations. The Euro score best predicted the outcome of our patients. However, when the indication for surgery is to be determined in an individual patient, risk scores should be only considered as an orientation in the decision process.

BACKGROUND A significant number of patients with coronary artery disease is diagnosed with additional carotid artery disease. This subset of patients has been identified as a high-risk group for cardiac and cerebral complications following surgical intervention. METHODS In a retrospective analysis we investigated the perioperative outcome of combined single-stage carotid endarterectomy (CEA) and coronary artery bypass grafting (CABG) in 63 patients operated between January 1989 and August 1998. In all of these patients, CEA was performed prior to CABG and before initiation of cardiopulmonary bypass. RESULTS Perioperative mortality rate was 7.9% (5/63) for simultaneous CEA and CABG and was due to cardiac complications in all patients. Postoperative unilateral neurological symptoms were diagnosed in 1 patient (1.7%) and were completely reversible. No neurologic events suggestive for permanent cerebral damage were observed during the 30 d postoperative period. CONCLUSIONS In our study combined single-stage CEA and CABG was associated with low cerebral morbidity and patient outcome was mainly determined by cardiac complications. In this subset of patients, simultaneous CEA and CABG appears to be a safe method.

This study investigated (cardiac) remodeling of the myocardial microvasculature in patients with terminal heart failure due to ischemic (ICM) and dilative (DCM) cardiomyopathy. Seventeen transmural left-ventricular (LV) biopsies (9 ICM and 8 DCM), taken from heart transplant recipients at transplantation (n=4) or during ventricular assist device implantation (n=13) were investigated by immunohistostaining for VEGFR-1 and VEGFR-2 as capillary markers and VEGFR-3, D2-40, PROX-1 and LYVE-1 as lymphatic markers. Results were compared to LV biopsies from 7 donor hearts (control). Compared to control, DCM hearts showed a significantly higher density of LYVE-1 positive lymphatics (p0.05), whereas no difference was seen for other markers. ICM hearts showed a significantly higher density of D2-40 positive lymphatics (p0.01) and a lower density of VEGFR-2 capillaries compared to control (p0.05). In comparison to normal donor hearts, ICM and DCM hearts showed a significantly different pattern of microvascular receptor expression. As distinct patterns were seen in ICM and DCM, the effect of microvascular remodeling may be substantially different between two clinically important causes of cardiomyopathy. Further research should be aimed at defining the impact of extracellular matrix composition and VEGF-related angiogenesis on the myocardial microvasculature at various stages of heart failure.

Patients with penetrating cardiac injury usually present with cardiac tamponade and shock upon hospital arrival. However, absence of hemodynamic depression does not exclude a potentially fatal injury of the heart. This article reports on a patient who developed neither hemodynamic depression nor ECG changes for several hours, despite two left ventricular lacerations with puncture of the LAD. Echocardiography is advocated as the diagnostic tool of choice, and it is emphasized that no penetrating objects should be removed from the wound before surgical access to the heart is established, as this may result in the sudden development of cardiac tamponade.

Decline in renal and cognitive function may complicate early recovery after coronary-artery bypass grafting. AT(1)-receptor antagonists have been demonstrated to be neuro- and renoprotective. Aim of ARTA, a prospective, double-blind, randomised and placebo controlled study, was to detect whether preoperative treatment with candesartan influences postoperative cognitive and renal function.One hundred and five patients eligible for coronary artery bypass graft surgery (65-85 years old, all suffering from hypertension and coronary artery disease, with stable kidney function) were randomized to candesartan (8 mg od) or placebo for between 8 and 11 days prior to surgery. Existing ACE-inhibitor/angiotensin receptor antagonist-therapy had to be stopped prior to the study. Validated cognitive function tests (trail making, Horn's perfomance III und VI, divided attention and change of reaction, memory - immediate and delayed recall, digit span) were performed preoperatively, 1 week and 3 months after surgery. Renal function was assessed by creatinine clearance on the day before, 1 week and 3 months after surgery.Eighty-seven patients (n = 43 Candesartan, n = 44 placebo) were included in the ITT-population for analysis. Drug treatment had no adverse effect on perioperative blood pressure. Only five patients experienced a period of hypotension during introduction of anaesthesia (Candesartan 1/44, placebo 4/44). One week as well as three months after surgery, there were no differences in relevant cognitive function parameters compared to the status prior to surgery, independent from treatment. Creatinine clearance showed a clear decrease one week after surgery with a minor further reduction observed 3 months after surgery, but there was no difference between Candesartan and placebo treated patients. Between both groups, there were no significant differences in the number of adverse events and number of patients with adverse events nor in the incidence of renal failure with consecutive dialysis and cerebral strokes (candesartan 2, placebo 5) and possibly drug related severe adverse events.This randomised placebo-controlled and prospective study in elderly patients does not support previous reports suggesting a substantial impairment of cognitive function after coronary artery bypass graft surgery. Preservation of cognitive and renal function was independent of pre-surgical administration of candesartan.

1. The present study investigates the vasoselectivity of lercanidipine (LER), a 1,4-dihydropyridine calcium channel blocker, compared with amlodipine (AML) and nifedipine (NIF) in human cardiovascular tissue. Experiments were performed either in human left ventricular failing myocardium (orthotopic heart transplants) or in isolated right atrial trabeculae and isolated vessel preparations of arteria mammaria obtained from patients undergoing aortocoronary bypass operation. 2. The obtained rank order for the L-type Ca2+ channel affinity in human tissue was LER > NIF >or= AML. Lercanidipine had the lowest negative inotropic efficacy (1 micromol/L LER: 60.3% basal < AML: 79.1% basal < NIF: 92.4 basal) and potency (IC50 NIF: 3.5 nmol/L < AML: 48 nmol/L < Ler: 127 nmol/L) in right atrial trabeculae. 3. The vasorelaxant potency of LER (IC50 0.5 nmol/L) and AML (IC50 0.8 nmol/L) was similar and significantly increased compared with that of NIF (IC50 5.9 nmol/L) in arteria mammaria preparations of the very same patients. 4. The following rank order was obtained for vasoselectivity: LER (260) < AML (60) < NIF (0.6). 5. The pharmacological effects of LER and AML were still present 2 h after drug washout. 3. Lercanidipine is characterized by a high vasoselectivity and a prolonged interaction with the L-type calcium channel in human cardiovascular tissue This may be advantageous, especially in the treatment of patients with arterial hypertension.

AIMS: Transvenous AV-synchronous pacing in children started with the invention of smaller sized VDD leads and miniaturization of pacemakers. Whether or not this is a favourable long-term therapy was retrospectively investigated by us based on data from our records. METHODS: From May 1977 to July 2001 we implanted pacemakers in 104 children younger than 15 years of age. In 55 patients transvenous leads were implanted. Twelve of these (21.8 %) received a VDD pacemaker for hemodynamic reasons. RESULTS: Ages ranged from 11 months to 14.5 years (mean 7.7 +/- 4.3 y). Sizes of the children ranged from 67 to 141 cm (mean 105.9 +/- 15.5 cm) and body weight ranged from 5.3 to 62.0 kg (mean 22.5 +/- 9.8 kg). The mean follow-up period was 47.5 +/- 15.1 months. In 86.3 % of the time during follow-up pacemakers of which we obtained data were working in the VDD mode. Five of the twelve VDD patients (41.7 %) had to be reoperated because of severe traction on the leads. In all five patients the VDD systems were explanted and the patients changed to dual chamber pacemakers. The period of time between implantation and VDD lead explantation ranged from 24 to 74 months (48.6 +/- 18.5). CONCLUSIONS: VDD pacemakers can be implanted safely even in children with a low complication rate perioperatively. 41.7 % of our VDD patients had to be reoperated within the surveillance time because of severe lead tension due to thoracic growth. In our experience VDD pacemakers in smaller children seem to be a temporary solution to bridge AV-synchrony from a young age to DDD pacing in young adulthood.

Objectives: Oxygen-derived free radical formation induced by cardiopulmonary bypass (CPB) may contribute to renal dysfunction associated with cardiac surgery. As anti-oxidants have been shown to attenuate free radical-induced renal dysfunction in medical patients, we hypothesized that the anti-oxidant N-acetylcysteine (NAC) protects renal function in patients subjected to cardiac surgery on CPB. Material and Methods: Forty coronary artery surgery patients (66±9[SD] years, 9 women and 31 men) with normal preoperative renal function (serum creatinine

Objectives: Nuclear factor κ-B (NFkB), a transcription factor, has been indicated to play a role in the development of numerous pathological states such as myocardial ischemia-reperfusion (I/R), apoptosis, and ischemic preconditioning. As both myocardial ischemia and reperfusion (by reactive-oxygen intermediates) can activate NFkB we investigated the impact of the antioxidant N-Acetylcysteine (NAC) on NFkB-regulation in patients subjected to cardioplegic arrest (CA) on cardiopulmonary bypass (CPB). Material and Methods: Forty coronary artery surgery patients (66±9[SD] years, 9 women and 31 men) subjected to cardiopulmonary bypass (CPB) and cardioplegic arrest were randomized in a double-blind fashion to receive either NAC (100mg/kg into CPB prime followed by infusion at 20mg/kg/h; n=20) or Placebo (n=20). We collected transmural LV biopsies prior to CPB (baseline) and at CPB-end. LV specimen were immuno-cytochemically stained against active NFkB and phosphorylated IκBα (activates NFkB). Staining was quantitatively determined using densitometry and the number of positive capillaries per viewfield (cpv) was counted. Results: At CPB-end both NFkB and IκBα were unchanged in endothelial cells of controls compared to baseline (45.6±7.6 vs. 49.9±7.1 and 36.8±6.1 vs. 47.5±8.6 cpv, p>0.05, respectively). In NAC, NFkB and IκBα in endothelial cells were significantly decreased at CPB-end (19.8±1.7 vs. 39.1±4.1 cpv, p

Bleeding after heart operations remains a common complication and contributes to morbidity and death. Recent studies have suggested that antiplatelet therapy (APT) may not increase homologous blood requirements in coronary bypass surgery. The purpose of this study was to examine the influence of APT therapy on haemorrhage and transfusion requirements in patients undergoing coronary artery bypass (CABG) on cardiopulmonary bypass (CPB).Records from 290 consecutive patients who underwent CABG with CPB were retrospectively reviewed, including 145 patients who received APT within 5 days prior to surgery and 145 control patients (CON). Blood loss was measured up to 24 h. Demographic and clinical patient data were collected until hospital discharge.Both groups were well matched with respect to demographic and intra-operative data. There was significantly (p0.0005) more mediastinal tube drainage at 24 h in the APT group (1123 mL +/- 537 mL) compared to CON patients (874 mL +/- 351 mL). In addition, the APT group received significantly more units of blood (APT: 2.6 +/- 2.5 vs CON: 1.6 +/- 1.8; p0.0005), platelet units (APT: 1.2 +/- 1.8 vs CON: 0.2 +/- 0.8; p0.0005), and fresh frozen plasma units (APT: 2.0 +/- 2.2 vs CON: 1.3 +/- 2.0; p = 0.01).This study suggests consideration should be given to delaying elective CABG for patients who have received APT treatment until APT is discontinued for at least 5 days.

Aprotinin (AP) reduces blood loss and transfusions after cardiopulmonary bypass (CPB), but may sensitise patients and is expensive. Tranexamic acid (TA) has less side-effects, but data regarding its efficacy are controversial. The aim of our prospective, randomised, double-blind study was to compare the impact of AP vs. TA on drainage blood loss and transfusion requirements in patients undergoing first time CABG on CPB.One hundred and twenty adult patients were randomised to receive either high-dose AP according to Hammersmith or a total of 2 g TA. Perioperative blood products were transfused in a standardised fashion. Blood loss was measured up to 24 h. Demographic and clinical patient data were collected until hospital discharge.The data from 118 patients (TA: n = 58, AP: n = 60) who completed the study according to protocol were analysed. Blood loss at 24 h postoperation in TA patients was significantly higher (896 +/- 354 ml) as compared to AP patients (756 +/- 347 ml; p = 0.03). TA patients received 1.5 +/- 1.5 units of red blood cells (AP: 1.5 +/- 1.7, p = 1.0), 1.3 +/- 2.0 units of fresh frozen plasma (AP: 1.0 +/- 2.0, p = 0.38) and 0.5 +/- 1.4 units of platelets (AP: 0.2 +/- 0.7, p = 0.15). Clinical data, including perioperative myocardial infarction rate, acute renal failure, mechanical ventilation, hospital stay and mortality, were not significantly different between either group.Our data show a difference in blood loss between TA and high-dose AP. Although statistically significant, it has little clinical relevance, because perioperative transfusion requirements were similar for both groups. Thus, TA appears to be a cost-effective alternative to AP in primary CABG patients.

BACKGROUND: Myocardial edema is a common finding in congestive heart failure, transplant rejection, and cardiomyopathy. Although pathological alterations in the lymphatic morphology are part of the underlying disease, knowledge on these changes is limited. However, lymphatic morphology may be investigated by immunohistochemical staining for fms-like tyrosine 4 kinase (flt-4), which is specific for lymphatic endothelium in adult tissue. METHODS: We used myocardial tissue of ventricular out flow tract taken from five human semilunar valves harvested as allografts but unsuitable for implantation for analysis, performing immunohistochemical staining for flt-4 with a commercially available antibody. Lymphatic morphometry was completed according Gundersen method. RESULTS: Immunohistochemical staining for flt-4 resulted in successful labeling of lymph capillaries in adult human myocardium. Lymph capillary density was calculated as 50.7 +/- 12.5 per mm2 and average diameter was 3.7 +/- 0.7 microm. Conclusions. Lymph capillary morphology in human myocardium may be successfully determined by immunohistochemical staining for flt-4. Tissue samples as small as myocardial biopsies may be used for analysis. Using this method, morphological changes in myocardial lymphatics may be investigated in various cardiovascular diseases.

Objective: The role of nitric oxide (NO) in myocardial ischemia/reperfusion is controversial. While some studies have shown cardioprotective effects of NO, others suggested that increased myocardial NO release secondary to ischemia may contribute to reperfusion injury. However, the impact of cardioplegia-induced myocardial ischemia/reperfusion on the activity of the NO-producing enzyme constitutive NOsynthase (cNOS or NOS-III) has not been investigated. Methods: Twenty elective CABG patients were randomized to receive myocardial protection using either intermittent cold blood cardioplegia with ‘hot-shot’ (CBC; na 10) or continuous warm blood enriched with the ultrafast-acting b-blocker esmolol (WBE; na 10). We collected transmural LV biopsies prior to cardiopulmonary bypass (CPB), at the end of the cross-clamp period, and at the end of CPB. Specimen were subjected to immunocytochemical staining against myocardial NOS-III and cGMP using polyclonal antibodies. NOS-III activity was determined using TV-densitometry (gray units) and cGMP content using a semiquantitative score. Global myocardial metabolism was assessed by arterio-coronary sinus lactate concentration difference (a-csDLAC). For LV function determination we measured the fractional area of contraction (FAC) using TEE. Results: In CBC hearts a-csDLAC was significantly decreased following cross-clamp removal as compared to pre-CPB indicating global ischemia during cross-clamp. In contrast, a-csDLAC was unchanged in WBE hearts indicating absence of relevant ischemia in this group. In CBC hearts NOS-III activity did not change from pre-CPB (35.6 ^ 11.1 U) to the end of the cross-clamp period (38.0 ^ 8.1 U; Pa 0:2), but increased significantly to 48.5 ^ 12.1 U at the end of CPB following initial warm blood reperfusion (Pa 0:026). In WBE hearts NOS-III activity remained unchanged throughout (29.2 ^ 10.8, 35.1 ^ 11.8, and 32.2 ^ 14.7 U, respectively; P . 0:3). At the end of CPB, nine CBC hearts, but only one WBE heart showed increased cGMP content (Pa 0:002). Compared to pre-CPB, FAC in the CBC group was 109 ^ 25% following weaning off CPB (Pa 0:26), but was slightly decreased to 87 ^ 22% at 4 h post-CPB (Pa 0:03). In the WBE group FAC remained unchanged compared to pre-CPB throughout (103 ^ 21 and 96 ^ 37%, respectively; P . 0:5). Conclusions: Our data show that global myocardial ischemia and reperfusion induced by CBC is associated with myocardial NOS-III activation and increased cGMP content suggesting increased NO release. In contrast, avoidance of ischemia by use of WBE prevented NOS-III and c-GMP increase. As LV function was decreased at 4 h post-CPB in the CBC group, these data suggest that increased NO release secondary to NOS-III activation may have contributed to ischemia-reperfusion injury as has been shown experimentally. q 2000 Elsevier Science B.V. All rights reserved.

Background Myocardial protection during cardiac surgery in patients with acute ischemia after failed PTCA remains a challenge. Our recent experimental work demonstrated that continuous coronary perfusion with warm beta-blocker-(Esmolol) enriched blood may be a useful alternative to current cardioplegia techniques, especially for compromised hearts. This technique was applied in our last 12 patients after failed PTCA (beta-B). The purpose of this retrospective study was to compare this alternative myocardial protection technique with our standard technique of cold crystalloid cardioplegia (CP). Methods Between January 1994 and January 1998 fifty-five patients (beta-B: n = 12; CP: n = 43) underwent emergency coronary artery bypass grafting within 24 hours after failed PTCA. The mean age in beta-B patients was 62+/-9 (SD) years, and 33% were female (CP: 59+/-9 years, 42% female, p = NS). In beta-B patients 67% had myocardial infarction (MI) prior to coronary angioplasty, 67% had an ejection fraction (EF) >55%, and coronary vessel involvement (VI) was 2.1+/-0.7. CP patients had the following findings: MI rate 42%, EF >55% in 84%, VI was 2.2+/-0.6; p = NS. Operation commenced within 25-980 min after failed PTCA. Beta-B patients received 2.7+/-0.8 grafts during 45+/-20 min continuous coronary perfusion with Esmolol enriched blood, whereas CP patients had 3.0+/-1.1 grafts in 42+/-17 min cross-clamp time, p = NS. Results The total hospital stay was significantly (p = 0.004) shorter for beta-B patients (18+/-8 days) compared to CP patients (27+/-12 days). 30-days mortality rate was 9% in CP patients, whereas none of the beta-B patients died. Postoperative low cardiac output occurred in only one patient (8%) of the beta-B group and was treated with an intra-aortic balloon pump (IABP). Eight (19%) of the CP patients required an IABP and in five (12%) patients an additional ventricular assist device was necessary (LVAD: n = 4; RVAD: n = 1). The need for circulatory support with inotropes was significantly lower in beta-B patients. Cumulative postoperative dosage of dopamine and dobutamine was 34516+/-40400 microg/kg and 16221+/-26678 microg/kg respectively in CP patients. Beta-B patients required only 12457+/-14738 microg/kg (p = 0.02) dopamine and 5112+/-7381 microg/kg (p = 0.01) dobutamine. Perioperative myocardial infarction occurred in 53% of the CP patients and 17% of beta-B patients (p = 0.046). Total CKmax was significantly (p = 0.003) higher in CP patients (812+/-531 U/L) than in beta-B patients (457+/-265 U/L). Four CP patients (9%) had acute postoperative renal failure requiring hemofiltration, and 11 CP patients (26%) had acute postoperative pneumonia. In beta-B patients one patient (8%) suffered from postoperative pneumonia (p = NS) and no patient had renal failure (p = NS). Conclusion These clinical results appear to confirm our experimental data and suggest that continuous coronary perfusion with warm esmolol-enriched blood is superior to crystalloid cardioplegia in terms of in-hospital complications and mortality, especially for compromised hearts after failed PTCA.